1 Multicenter evaluation of a fully automated high-throughput SARS-CoV-2

2 antigen immunoassay

3

- 4 Dominik Nörz^{a*}, Flaminia Olearo^{a*}, Stojan Perisic^b, Matthias F. Bauer^c, Elena Riester^d, Tanja
- 5 Schneider^e, Kathrin Schönfeld^e, Tina Laengin^e, and Marc Lütgehetmann^a

- 7 ^aCenter for Diagnostics, Institute of Medical Microbiology, Virology and Hygiene, University Medical
- 8 Center Hamburg-Eppendorf (UKE), Hamburg, Germany
- 9 ^bHospital of Stuttgart, Institute for Clinical Chemistry and Laboratory Medicine, Stuttgart, Germany
- 10 ^cHospital of Ludwigshafen, Institute for Laboratory Medicine, Ludwigshafen, Germany
- ^dLabor Augsburg MVZ GmbH, Augsburg, Germany
- ^eRoche Diagnostics GmbH, Penzberg, Germany
- 13
- 14 *Contributed equally to this work
- 15
- 16 **Corresponding author**:
- 17 Marc Lütgehetmann
- 18 Institute of Medical Microbiology, Virology and Hygiene
- 19 Martinistraße 52
- 20 D-20246 Hamburg
- 21 mluetgeh@uke.de
- 22
- 23 Running title: SARS-CoV-2 antigen immunoassay

24 ABSTRACT

25 Introduction: Molecular testing for SARS-CoV-2 continues to suffer from delays and 26 shortages. Antigen tests have recently emerged as a viable alternative to detect patients 27 with high viral loads, associated with elevated risk of transmission. While rapid lateral flow 28 tests greatly improved accessibility of SARS-CoV-2 detection in critical areas, their manual 29 nature limits scalability and suitability for large-scale testing schemes. The Elecsys® SARS-30 CoV-2 Antigen assay allows antigen immunoassays to be carried out on fully automated 31 high-throughput serology platforms. **Methods:** A total of 3139 nasopharyngeal and 32 oropharyngeal swabs were collected at 3 different testing sites in Germany. Swab samples 33 were pre-characterized by RT-qPCR and consecutively subjected to the antigen 34 immunoassay on either the cobas e 411 or cobas e 801 analyzers. Results: Of the tested 35 respiratory samples, 392 were PCR positive for SARS-CoV-2 RNA. Median concentration was 2.95×10^4 (interguartile range [IQR] $5.1 \times 10^2 - 3.5 \times 10^6$) copies/mL. Overall sensitivity and 36 37 specificity of the antigen immunoassay were 60.2% (95% confidence interval [CI] 55.2–65.1) 38 and 99.9% (95% CI 99.6-100), respectively. A 93.7% (95% CI 89.7-96.5) sensitivity was achieved at a viral RNA concentration $\geq 10^4$ copies/mL (~cycle threshold (Ct) value<29.9). 39 40 Conclusion: The Elecsys SARS-CoV-2 Antigen assay reliably detected patient samples with viral loads of 10,000 copies/mL and higher. It thus represents a viable high-throughput 41 alternative for screening of patients, or in situations where PCR testing is not readily 42 43 available.

44 Keywords: Antigen immunoassay; High-throughput platform; SARS-CoV-2

45

46 Key Summary Points:

47 Why carry out this study?

48	• The SARS-CoV-2 pandemic has led to a surge in demand for reliable, mass diagnostic
49	tests worldwide.
50	• A thorough clinical evaluation of a fully automated high-throughput Elecsys [®] SARS-
51	CoV-2 Antigen assay on a total of 3139 clinical samples pre-characterized by
52	quantitative RT-PCR was carried out.
53	What was learned from the study?
54	• The assay demonstrated excellent specificity (99.9%) and good relative sensitivity,
55	with an overall sensitivity of 60.2% and a sensitivity of 93.7% for samples containing
56	$\geq 10^4$ viral RNA copies/mL.
57	• The Elecsys SARS-CoV-2 Antigen assay is a viable high-throughput, automated
58	alternative to manual lateral-flow antigen tests.
59	

60 INTRODUCTION

61	RT-qPCR remains the gold standard for detection of SARS-CoV-2 in clinical specimens due to
62	its unparalleled analytic accuracy [1, 2]. However, the sudden surge in demand for molecular
63	testing continues to overstretch the capacity of both diagnostic laboratories and reagent
64	suppliers, leading to reporting delays and sometimes inadequate availability of testing where
65	it is urgently needed. SARS-CoV-2 antigen immunoassays have recently emerged as an
66	alternative to nucleic acid amplification tests, most prolifically in the form of rapid, point-of-
67	care, lateral flow tests (LFTs) [3-5]. Despite their inherent disadvantage in sensitivity
68	compared with PCR, mathematical modeling suggests that tests could be effective for
69	infection control if appropriate testing frequency were adopted [6]. Using currently available
70	rapid antigen tests for mass testing does however bring about additional challenges, as this
71	assay format is highly manual in nature and largely unsuitable for automation. Moving the
72	SARS-CoV-2 antigen assay from LFT to a high-throughput immunoanalyzer using
73	electrochemiluminescence detection technology could improve those issues, while further
74	increasing overall testing capacity. The aim of this study was to evaluate the sensitivity and
75	specificity of the new fully automated Elecsys® SARS-CoV-2 Antigen assay, using samples
76	characterized by the gold standard: RT-qPCR.

77

78 **METHODS**

79 Samples

In this multicenter study, nasopharyngeal and oropharyngeal samples were tested following
 routine diagnostics at the University Medical Center Hamburg-Eppendorf, the Hospital of

82	Stuttgart, and Hospital Ludwigshafen (Table S1). Overall, the study comprised a total of 3139
83	nasopharyngeal and oropharyngeal swab samples, including 1331 samples from the Hospital
84	of Stuttgart, 1058 samples from University Medical Center Hamburg-Eppendorf, and 647
85	samples from Hospital Ludwigshafen, as well as 103 banked nasopharyngeal samples in
86	universal viral transport (UVT) system from a commercial vendor (Boca Biolistics, Pompano
87	Beach, FL, USA). Specimens were collected in November 2020, in 3 mL of Copan Universal
88	Transport Medium (UTM-RT, Copan, Brescia, Italy) or BD Universal Viral Transport (UVT,
89	Becton, Dickinson, Sparks, MD, USA) using flocked swabs.
90	This study was conducted in accordance with applicable regulations, the study protocol
91	provided by Roche Diagnostics, and the principles of the Declaration of Helsinki. The use of
92	anonymized remnant samples material was approved by ethical review committees prior to
93	study initiation (ethics committee names and approval numbers: Ethik-Kommission bei der
94	Landesärztekammer Baden-Württemberg; F-2020-154 [Stuttgart]; Ethik-Kommission der
95	Ärztekammer Hamburg: WF-184/20 [Hamburg]; Ethik-Kommission bei der
96	Landesärztekammer Rheinland-Pfalz: 2020-15449[Ludwigshafen]).
97	

98 Antigen Assay and RT-qPCR

- 99 Antigen detection was performed at two testing sites (University Medical Center Hamburg-
- 100 Eppendorf (UKE) and testing site of Augsburg) using the Elecsys SARS-CoV-2 Antigen assay on
- 101 the cobas e 411 and cobas e 801 immunoanalyzers. The Elecsys SARS-CoV-2 Antigen assay
- 102 (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) is an automated
- 103 electrochemiluminescence immunoassay (ECLIA), developed for *in vitro* qualitative detection
- 104 of SARS-CoV-2 antigen. It utilizes monoclonal antibodies directed against the SARS-CoV-2

nucleocapsid protein in an antibody sandwich assay format for the detection of SARS-CoV-2 in upper respiratory tract specimens [7]. The time to result for the assay can be as little as 18 minutes, and the analyzer automatically calculates a cut-off based on the measurement of two calibrators: one negative (COV2AG Cal1) and one positive (COV2AG Cal2). The results obtained are interpreted as recommended by the manufacturer as either 'reactive' or 'nonreactive' in the form of a cut-off index (COI), i.e. 'non-reactive' if COI <1.0 or 'reactive' if COI \geq 1.0.

RT-qPCR testing was performed with the qualitative cobas® SARS-CoV-2 assay on the cobas® 112 6800 system (Roche Molecular Systems, Inc., Branchburg, NJ, USA), according to 113 manufacturer's instructions [8]. Quantification was performed using cycle threshold (Ct) 114 values of Target-2 (envelope protein coding gene) [9] using reference material by Qnostics 115 Ltd. (Glasgow, UK) as the quantification standard. The formula for conversion Ct value to 116 117 $\log 10 \text{ copies/mL}$ is (Ct × -0.30769) +13.2. The lower limit of quantification was set to Ct=33 118 corresponding to 1000 copies SARS-CoV-2 RNA/mL, in accordance with previous studies [9]. It has to be noted that the PCR test and guantification standard used for generating 119 120 quantitative results were not recommended for this purpose by the respective 121 manufacturers and reliability is expected to be lower than commercial quantitative solutions once they become available, which represents a limitation of this study. 122

123

124 Statistical Analysis

Sensitivity and specificity, including 95% confidence intervals (CIs), were assessed as per
Altman [10]. Pearson correlation was used for linear regression. The significance threshold

- 127 was set at a two-sided alpha value of 0.05. Statistical analysis was performed with STATA
- 128 (version 15) and GraphPad Prism (version 86 9.0.0).
- 129

130 Data availability

- 131 Qualified researchers may request access to individual patient level data through the clinical
- 132 study data request platform (https://vivli.org/). Further details on Roche's criteria for eligible
- 133 studies are available here: https://vivli.org/members/ourmembers/. For further details on
- 134 Roche's Global Policy on the Sharing of Clinical Information and how to request access to
- 135 related clinical study documents, see here:
- 136 https://www.roche.com/research and development/who we are how we work/clinical
- 137 trials/our commitment to data sharing.htm.
- 138

139 **RESULTS**

140	A total of 3139 respiratory samples were analyzed in this study (Table S1). Three hundred
141	and ninety-two samples were SARS-CoV-2 RNA positive and 2747 samples were SARS-CoV-2
142	RNA negative. For PCR-positive samples, 79/392 (20.2%) patients were asymptomatic and
143	79.8% (313/392) were symptomatic, with 47.6% (149/313) of samples collected within the
144	first 5 days of symptom onset. The median concentration of viral RNA was 2.95×10^4 SARS-
145	CoV-2 copies/mL (interquartile range [IQR] 5.1×10 ² –3.5×10 ⁶ SARS-CoV-2 RNA copies/mL;

- **Fig. 1a**). In total, 236/392 samples were detected as reactive for SARS-CoV-2 antigen with
- the Elecsys assay, with a median COI value of 46.0 (IQR 6.0–701.3). Distribution of the results
- 148 for the PCR-positive and PCR-negative groups is shown in Fig. 1b. The overall sensitivity and

149	specificity were 60.2% (95% Cl 55.2–65.1, number of samples [N]=392) and 99.9% (95% Cl				
150	99.6–100, N=2747), respectively (Table 1). The cumulative sensitivity was 93.7%, 100%, and				
151	100% for samples with >10,000 copies (~Ct <29.9), 100,000 copies (~Ct <26.6), and 1,000,000				
152	copies (~Ct <23.0) (Table 1), respectively.				
153	For samples from symptomatic patients, the assay reached an overall relative sensitivity of				
154	68.4% (95% CI 62.9–73.5, N=313), increasing to 83.2% (95% CI 76.2–88.8, N=149) if				
155	symptoms had manifested within the last 5 days (Table S2). On the other hand, the overall				
156	sensitivity observed in asymptomatic patients was only 27.8% (95% Cl 18.3–39.1, N=79).				
157	Relative sensitivities corresponded with high RNA levels and gradually decreased as RNA				
158	levels decreased. A considerable increase in sensitivity was observed when analysis was				
159	limited to samples containing >10,000 copies/mL, reaching 95.9% (95% Cl 92.2–98.2, N=197)				
160	for symptomatic patients and 76.9% (95% CI 56.4–91.0, N=26) for asymptomatic patients				
161	(Table S2).				
162	To analyze the overall assay performance, samples were sorted by SARS-CoV-2 RNA				
163	copies/mL and individual sensitivities calculated for sets of 20 samples (shown using a heat				
164	map in Fig. 2A). Of note, the sensitivity of the assay was 95% and 50% at concentrations of				
165	around 2×10^5 and 2×10^4 – 5×10^3 viral copies/mL, respectively, but <10% for samples with <10 ³				
166	copies/mL. When the analysis was focused on samples containing RNA levels beyond 95%				
167	sensitivity of the immunoassay (10,000 copies/mL; Ct <29.9), a significant linear correlation				
168	was observed between the Elecsys SARS-CoV-2 Antigen assay COI value and SARS-CoV-2 RNA				
169	copies/mL (p=<0.0001; r ² =0.786; Fig. 2B). Also, in this group, a sensitivity of 98.3% (95% CI				
170	94.0–99.8) was achieved in the sub-analysis of patients tested less than 5 days after				
171	symptom onset.				

172 **DISCUSSION**

173	The introduction of rapid SARS-CoV-2 antigen testing into the market was met with a lot of
174	initial enthusiasm due to the promise of broad availability and easy application. While there
175	are many different methods for antigen detection in clinical practice, such as enzyme-linked
176	immunosorbent assays and ECLIAs, the first wave of commercial tests consisted
177	predominantly of rapid, point-of-care LFTs with optical read-outs. Preliminary performance
178	data demonstrated good sensitivity in high-viral-load samples, but low concentrations of
179	virus are frequently missed, thus leading to the sobering conclusion that antigen tests
180	cannot provide the same definitive results as RT-qPCR [5, 11-13]. Although PCR tests are
181	analytically superior, their effectiveness for infection control has often been hampered by
182	supply shortages and reporting delays.
183	Recent studies have shown a correlation between the probability of recovering infectious
184	virus from clinical samples and the time of onset of symptoms, as well as RNA
185	concentrations (>1 $\times 10^{6}$ copies/mL) within the specimen [14, 15]. This suggests that the risk
186	of transmission is highest during the early stages of disease, when viral titers are at their
187	peak, which would also facilitate detection by antigen test. A recent study by McKay et al.
188	[16] demonstrated good correlation between positive antigen-test and positive viral culture;
189	however, negative viral culture should not be misinterpreted as a reliable indicator for ruling
190	out transmission risk. It has further been suggested that a low sensitivity test can be just as
191	effective at detecting infections as a highly sensitive one, if testing can be made possible at
192	increased frequency [6]. Most currently available SARS-CoV-2 antigen tests utilize a rapid,
193	point-of-care LFT format, thus relying on a high degree of human interaction. They are
194	unsuitable for automation and additional human operators are required at the same

195 proportion as testing capacity is scaled up. While there are clear benefits of a point-of-care

- 196 test that can be carried out with minimal training and requiring no specialized equipment
- 197 [17], testing en masse (e.g. in healthcare facilities) is vastly more efficient when performed
- 198 automatically using high-throughput immunoassay platforms.
- 199 In this study, we stratified samples to assess the relative sensitivity of the new Elecsys SARS-
- 200 CoV-2 Antigen assay for the cobas immunoassay analyzer systems using the gold standard,
- 201 RT-qPCR. Although the overall relative sensitivity for the entire sample set was 60.2%,
- among those patients that were tested in the first 5 days from the onset of symptoms, the
- sensitivity increased to 83.2%. Furthermore, the Elecsys SARS-CoV-2 Antigen assay was able
- to detect 93.7% of patients with elevated risk of transmission (Ct <30 and accordingly
- c(RNA)> 10,000 copies/mL). Overall relative specificity was determined as 99.9% in a total of
- 206 2747 negative samples. These results are in line with existing preliminary data on the clinical
- 207 performance of other available SARS-CoV-2 antigen tests [12, 18], including other high-
- throughput SARS-CoV-2 antigen tests like the Lumipulse [19], demonstrating a cumulative
- sensitivity of 55.2% compared with PCR.
- 210 The main limitation of the present study is that it is not a head-to-head comparison of the
- 211 different systems on the market, and future investigation is needed to address this concern.
- However, the high-throughput Elecsys SARS-CoV-2 Antigen assay might be a valuable
- analytic option in the coming months in the struggle to control the pandemic.
- 214

215 **CONCLUSIONS**

The novel Elecsys SARS-CoV-2 Antigen immunoassay showed good performance in a broad
 set of clinical samples compared to RT-PCR. It demonstrated a high reliability in detecting
 10

218	samples containing hig	h concentrations of viral	RNA, indicative of high transmission

219 potential. Furthermore, a relative specificity of 99.9% ensures a minimal rate of false-

220 positives, consequently saving resources on confirmation-testing and unnecessary

221 quarantine. The ability to run the test on high-throughput immunoassay platforms, and a

time-to-result of approximately 18 minutes, allow for en masse deployment of SARS-CoV-2

antigen testing, for example in the context of centralized large-scale testing schemes.

224

225 **ACKNOWLEDGMENTS**

226 *Funding.* This study was funded by Roche Diagnostics GmbH (Mannheim, Germany).

227

Authorship. All named authors meet the International Committee of Medical Journal Editors
(ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work
as a whole, and have given their approval for this version to be published.

231

232 Authorship Contributions. Tina Laengin, Tanja Schneider, and Kathrin Schönfeld developed 233 the study conceptualization and design and study protocol, and managed the study conduct, 234 database generation and data validation. Marc Lütgehetmann, Stojan Perisic, and Matthias 235 F. Bauer provided sample material and Marc Lütgehetmann, Stojan Perisic, and Elena Riester generated data during study testing. Marc Lütgehetmann, Tanja Schneider, and Tina Laengin 236 237 conceived the original idea of the manuscript. Dominik Nörz, Flaminia Olearo, Marc 238 Lütgehetmann, and Tanja Schneider formally analyzed the data and its representations for 239 the manuscript. Dominik Nörz, Marc Lütgehetmann, and Flaminia Olearo drafted the

240 manuscript and interpreted the data with critical input from Tanja Schneider and Tina

- Laengin. All authors reviewed and revised the manuscript and approved it for publication.
- 242

243	Medical Writing, Editorial, and Other Assistance. The authors thank: Serology team of the
244	University Medical Center Hamburg-Eppendorf, Institute of Medical Microbiology, Virology
245	and Hygiene; the laboratory team of the Institute of Laboratory Diagnostics, Hygiene and
246	Transfusion Medicine at the Klinikum Ludwigshafen; the Corona specimen acquisition team
247	and its Coordinator Mr. OA Christian Menzel (Clinic of Stuttgart), Corona testing facility team
248	(Clinic of Stuttgart) as well as Ms. Pauline Weissleder and Ms. Sina Semenowitsch (Clinic of
249	Stuttgart) for great help with specimen handling and data processing; Sigrid Reichhuber,
250	Janina Edion, and Yvonne Knack (Roche Diagnostics) for management of investigation sites,
251	data acquisition, and study monitoring. Medical writing support, under the direction of the
252	authors, was provided by Tina Patrick (Elements Communications Ltd, Westerham, Kent, UK)
253	and was funded by Roche Diagnostics International Ltd, Rotkreuz, Switzerland.
254	COBAS, COBAS E and ELECSYS are trademarks of Roche.
255	
256	Disclosures. Tanja Schneider, Kathrin Schönfeld, and Tina Laengin are employees of Roche
257	Diagnostics GmbH. Marc Lütgehetmann has received speaker's honoraria and related travel
258	expenses from Roche Diagnostics. Elena Riester has received speaker's honorarium from
259	Roche. Stojan Perisic, Flaminia Olearo, Matthias F. Bauer and Dominik Nörz have no conflicts
260	to report.

261

- 262 *Compliance with Ethics Guidelines.* This study was conducted in accordance with applicable
- regulations, the study protocol provided by Roche Diagnostics, and the principles of the
- 264 Declaration of Helsinki of 1964, and its later amendments. The use of anonymized remnant
- samples material was approved by ethical review committees prior to study initiation (ethics
- 266 committee names and approval numbers: Ethik-Kommission bei der Landesärztekammer
- 267 Baden-Württemberg; F-2020-154 [Stuttgart]; Ethik-Kommission der Ärztekammer Hamburg:
- 268 WF-184/20 [Hamburg]; Ethik-Kommission bei der Landesärztekammer Rheinland-Pfalz:
- 269 2020-15449[Ludwigshafen]).

270

- 271 **Data Availability.** The datasets generated during and/or analyzed during the current study
- are available from the corresponding author on reasonable request.

273

275 **REFERENCES**

- 276 1. World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-
- 19) in suspected human cases. 2020. <u>https://www.who.int/publications-</u>
- 278 detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-
- 279 <u>20200117</u>. Accessed June 04 2021.
- 280 2. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-

nCoV) by real-time RT-PCR. Euro Surveill 2020;25:2000045.

- 282 https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.
- 283 3. Centers for Disease Control and Prevention. Interim Guidance for Antigen Testing for
- 284 SARS-CoV-2. 2021. https://www.cdc.gov/coronavirus/2019-
- 285 <u>ncov/lab/resources/antigen-tests-guidelines.html</u>. Accessed June 04 2021.
- 4. Igl[®]i Z, Velzing J, van Beek J, et al. Clinical evaluation of the Roche SD Biosensor rapid
- 287 antigen test for SARS-CoV-2 in Municipal Health Service Testing Site, the Netherlands.
- 288 Emerg Infect Dis 2021;27:1323–9. https://doi.org/10.3201/eid2705.204688.
- 289 5. Olearo F, Nörz D, Heinrich F, et al. Handling and accuracy of four rapid antigen tests
- for the diagnosis of SARS-CoV-2 compared to RT-qPCR. J Clin Virol 2021; 137:104782.
- 291 https://doi.org/10.1016/j.jcv.2021.104782.
- 292 6. Mina MJ, Parker R, Larremore DB. Rethinking covid-19 test sensitivity a strategy
- for containment. N Engl J Med 2020; 383:e120.
- 294 https://doi.org/10.1056/NEJMp2025631.
- 295 7. Roche Diagnostics GmbH. Elecsys[®] Anti-SARS-CoV-2 method sheet v1. 2021.
- 296 https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-
- 297 <u>2.html</u>. Accessed June 04 2021.

- 298 8. Roche Molecular Systems Inc. cobas® SARS-CoV-2 Qualitative assay for use on the
- 299 cobas[®] 6800/8800 Systems. 09179917001-05EN. Doc Rev. 5.0.
- 300 https://www.fda.gov/media/136049/download. Accessed February 11 2021.
- 301 9. Nörz D, Frontzek A, Eigner U, et al. Pushing beyond specifications: Evaluation of
- 302 linearity and clinical performance of a fully automated SARS-CoV-2 RT-PCR assay for
- 303 reliable quantification in blood and other materials outside recommendations. J Clin

304 Virol 2020;132:104650. https://doi.org/10.1016/j.jcv.2020.104650.

- 305 10. Altman DG, Bland JM. Diagnostic tests. 1: Sensitivity and specificity. BMJ 1994;
- 306 308:1552. https://doi.org/10.1136/bmj.308.6943.1552.
- 307 11. Scohy A, Anantharajah A, Bodéus M, et al. Low performance of rapid antigen
- 308 detection test as frontline testing for COVID-19 diagnosis. J Clin Virol

309 2020;129:104455. https://doi.org/10.1016/j.jcv.2020.104455.

- 310 12. Corman VM, Haage VC, Bleicker T, et al. Comparison of seven commercial SARS-CoV-
- 311 2 rapid Point-of-Care Antigen tests. Lancet Microbe 2021.
- 312 https://doi.org/10.1016/S2666-5247(21)00056-2.
- 313 13. Krüger LJ, Gaeddert M, Tobian F, et al. Evaluation of the accuracy and ease-of-use of
- 314 Abbott PanBio A WHO emergency use listed, rapid, antigen-detecting point-of-care
- diagnostic test for *SARS-CoV-2*. PLoS One 2021;16:e0247918.
- 316 https://doi.org/10.1371/journal.pone.0247918.
- 317 14. Jefferson T, Spencer EA, Brassey J, Heneghan C. Viral cultures for COVID-19 infectious
- 318 potential assessment a systematic review. Clin Infect Dis 2020; ciaa1764.
- 319 https://doi.org/10.1093/cid/ciaa1764.

- 320 15. Woelfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized
- 321 patients with 2019. Nature 2020: 581;465–9. https//.doi.org/10.1038/s41586-020-
- 322 2196-x.
- 323 16. McKay SL, Tobolowsky FA, Moritz ED, et al. Performance evaluation of serial SARS-
- 324 CoV-2 rapid antigen testing during a nursing home outbreak. Ann Intern Med
- 325 2021;M21-0422. https//.doi.org/10.7326/M21-0422.
- 17. Hoehl S, Schenk B, Rudych O, et al. At-home self-testing of teachers with a SARS-CoV-
- 327 2 rapid antigen test to reduce potential transmissions in schools. medRxiv 2020.
- 328 https://doi.org/10.1101/2020.12.04.20243410.
- 329 18. Weitzel T, Legarraga P, Iruretagoyena M, et al. Head-to-head comparison of four
- 330 antigen-based rapid detection tests for the diagnosis of SARS-CoV-2 in respiratory
- 331 samples. bioRxiv 2020: https://doi.org/10.1101/2020.05.27.119255.
- 332 19. Hirotsu Y, Maejima M, Shibusawa M, et al. Comparison of automated SARS-CoV-2
- antigen test for COVID-19 infection with quantitative RT-PCR using 313
- 334 nasopharyngeal swabs, including from seven serially followed patients. Int J Infect Dis
- 335 2020;99:397–402. https://doi.org/10.1016/j.ijid.2020.08.029.

337 Figures and Tables

338

339 Figure 1.

- a) Number of positive samples relative to cobas SARS-CoV-2 PCR titer [copies/mL]; b) COI values of
- 341 Elecsys SARS-CoV-2 Antigen test from 2747 cobas SARS-CoV-2 PCR-negative and 392 cobas SARS-
- 342 CoV-2 PCR-positive samples.

343

344 Figure 2.

- a) Elecsys SARS-CoV-2 Antigen assay results in relation to cobas SARS-CoV-2 RNA copies/mL. Dark
- 346 blue fields represent positive and light blue fields represent negative Elecsys SARS-CoV-2 Antigen test
- results. On left side, sensitivity was calculated every ≈ 20 samples included in the interval of the
- 348 heatmap (copies/mL); b) Correlation between Elecsys SARS-CoV-2 Antigen assay (log10 [COI], y-axis)
- 349 and cobas SARS-CoV-2 PCR assay (log10 [RNA copies/mL], x-axis). Closed blue circles: measurements
- 350 within linear range considered for the trendline and correlation (SARS-CoV-2 RNA $\geq 10^5$ copies/mL;
- 351 COI ≥1). Open blue circles: measurements outside of the linear range of Elecsys SARS-CoV-2 or one
- 352 cobas SARS-CoV-2 PCR Target negative, not considered for trendline and correlation. p=<0.0001;
- 353 r²=0.786.
- 354 Ag, antigen; COI, cut-off index; Ct, cycle threshold

356 Table 1. Sensitivity and specificity results for the Elecsys SARS-CoV-2 Antigen assay

357

	cobas SARS-CoV-2 assay	N total	Elecsys SARS-CoV-2 Antigen negative	Elecsys SARS-CoV-2 Antigen positive	Relative sensitivity/specificity, % (95%, Cl two-sided)
	PCR positive	392	156	236	60.2 (55.2–65.1)
Relative	>10 ⁴ copies/mL (~Ct <29.9)	223	14	209	93.7 (89.7–96.5)
sensitivity	>10 ⁵ copies/mL (~Ct <26.6)	171	0	171	100 (97.9–100)
	>10 ⁶ copies/mL (~Ct <23.0)	122	0	122	100 (97.0–100)
Relative specificity	PCR negative	2747ª	2743	4	99.9 (99.6–100)

358

^a15 samples invalid with cobas SARS-CoV-2 RT-PCR, but negative with another SARS-CoV-2 RT-PCR test.

360 Cl, confidence interval; Ct, cycle threshold; N, number of samples



Relative sensitivity [intervall of ≈ 20 samples]



Negative Ag test

SARS-CoV-2 RNA [copies/ml]

а